Abstract:AbstractBackgroundMultiple imaging modalities have been individually shown to be useful in diagnosing Dementia with Lewy Bodies (DLB). Reduced striatonigral uptake on ioflupane‐SPECT reflects striatonigral dopamine dysfunction observed in DLB, while other imaging modalities assess different aspects of DLB, which potentially work complementarily when used together. We assessed how well ioflupane‐SPECT differentiates DLB from Alzheimer’s Disease Dementia (ADem) and whether adding another imaging modality to ioflupane‐SPECT would provide additional value.MethodIoflupane‐SPECT, MRI, FDG‐PET, and PiB‐PET were assessed on 35 DLB and 14 ADem patients (including 12 patients with eventual autopsy confirmation). Striatonigral dopamine transporter uptake was evaluated semi‐quantitatively with ioflupane‐SPECT using DaTQUANT software (GE Healthcare) to calculate z‐scores of putamen uptake. Hippocampal volume was calculated with structural MRI, cingulate island sign (CIS) ratio with FDG‐PET, and global cortical PiB retention with PiB‐PET.ResultLower DaTQUANT z‐scores of putamen were observed in DLB patients compared to ADem patients (c‐statistic 0.896, p<0.001). Ioflupane‐SPECT showed higher c‐statistic in differentiating DLB from ADem than hippocampal volume on MRI (c‐statistic 0.718, p=0.034), CIS on FDG‐PET (c‐statistic 0.869, p=0.003), or global cortical PiB retention on PiB‐PET (c‐statistic 0.869, p=0.002), but some overlap between two diagnostic groups was still observed with the single imaging modality. Among these imaging modalities, ioflupane‐SPECT was the only modality correlated with the Unified Parkinson Disease Rating Scale (UPDRS) part III, while only PiB‐PET correlated with Montreal Cognitive Assessment (MoCA) test score. Adding another imaging modality to ioflupane‐SPECT enhanced c‐statistics (+MRI c‐statistic 0.931, p<0.001; +FDG‐PET c‐statistic 0.957, p=0.005; +PiB‐PET c‐statistic 0.955, p=0.007), and ioflupane‐SPECT in combination with both FDG‐PET and PiB‐PET showed the highest c‐statistic of 0.974 (p=0.043).ConclusionIoflupane‐SPECT is an excellent imaging modality to identify DLB by detecting striatonigral dopamine dysfunction which is strongly associated with motor impairment in DLB. Correlative neuroimaging with MRI, FDG‐PET, or PiB‐PET may add small incremental value in differentiation of DLB and ADem. Supported by NIH grants (AG016574, AG006786, AG015866, NS100620, AG062677), grant from GE Healthcare, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, the Deal Family Foundation, and the Little Family Foundation.

Utility of combining multiple parameters of 123 I-IMP SPECT and voxel-based morphometry MRI using a multiparametric scoring system for differentiating dementia with Lewy bodies from Alzheimer's disease

Utility of neuromelanin-sensitive MRI in the diagnosis of dementia with Lewy bodies

The usefulness of combined analysis using CIScore and VSRAD parameters for differentiating between dementia with Lewy body and Alzheimer's disease

Validation of the cingulate island sign with optimized ratios for discriminating dementia with Lewy bodies from Alzheimer's disease using brain perfusion SPECT

Utility of Ioflupane‐spect with Multimodal Imaging in Dementia with Lewy Bodies

Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer’s disease

1H-proton magnetic resonance spectroscopy differentiates dementia with Lewy bodies from Alzheimer's disease.

Combining Multimodal Neuroimaging Biomarkers in the Diagnosis of Alzheimer’s Disease and Mild Cognitive Impairment

Capitalizing on Complementary FDG-PET and Florbetapir-Pet Data Sets to Distinguish Between Early and Late Mild Cognitive Impairment Using Multimodal Partial Least Squares

Diagnostic Sensitivity and Symptomatic Relevance of Dopamine Transporter Imaging and Myocardial Sympathetic Scintigraphy in Patients with Dementia with Lewy Bodies

Combinations of Multiple Neuroimaging Markers Using Logistic Regression for Auxiliary Diagnosis of Alzheimer Disease and Mild Cognitive Impairment

Multimodal analysis using [11C]PiB-PET/MRI for functional evaluation of patients with Alzheimer's disease

Multimodal classification of Alzheimer's disease and mild cognitive impairment

Statistical Parametric Mapping in Amyloid Positron Emission Tomography

Combining PET with MRI to Improve Predictions of Progression from Mild Cognitive Impairment to Alzheimer's Disease: an Exploratory Radiomic Analysis Study

Diagnostic Utility of Neuropsychological Performance and Quantitative MRI-based Measurement in Alzheimer Disease

Usefulness of texture analysis in 123I-FP-CIT for the differentiation of AD and DLB subtypes

Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders

Application of the Modified Qualitative Scoring of MMSE Pentagon Test in the Differential Diagnosis of Lewy Body Dementia and Alzheimer’s Disease

Combining PET with MRI to improve predictions of progression from mild cognitive impairment to Alzheimer’s disease: an exploratory radiomic analysis study

Multiparametric hippocampal signatures for early diagnosis of Alzheimer's disease using 18F-FDG PET/MRI Radiomics